Karolinska Development’s portfolio company receives approval to initiate a clinical Phase 1b trial with sevuparin in the Netherlands
10 November 2021 - 3:31AM
Karolinska Development’s portfolio company receives approval to
initiate a clinical Phase 1b trial with sevuparin in the
Netherlands
STOCKHOLM, SWEDEN – November 9, 2021. Karolinska Development AB
(Nasdaq Stockholm: KDEV) announces today that the portfolio company
Modus Therapeutics has received approval from the regulatory
authorities in the Netherlands to carry out a clinical Phase
1b-study with sevuparin, a potential new treatment of sepsis/septic
shock.
Sevuparin is an innovative drug candidate based on a
polysaccharide with the potential of limiting vascular injury and
plasma leakage in patients suffering from sepsis/septic shock or
other medical conditions involving systemic inflammation.
The aim of the planned randomized, placebo-controlled Phase
1b-study is to investigate the effect of intravenously
administrered sevuparin in dermal and systemic
lipopolysaccharide-induced (LPS) inflammation in healthy
individuals. The study will also evaluate sevuparin’s safety
profile in combination with a standard of care prophylactic,
anticoagulant heparin treatment. The study is designed using a
well-established and recognized model that is utilized to mimic the
early states of septic shock. Modus Therapeutics will conduct the
study in collaboration with the Center for Human Drug Research
(CHDR) in Leiden, the Netherlands, which is an experienced clinical
research actor carrying an extensive expertise in inflammatory
diseases and clinical studies.
“The regulatory go-ahead to start the Phase 1b study with
sevuparin constitutes an important step forward for Modus
Therapeutics. Sepsis/septic chock continues to pose a major
challenge, due to its high annual mortality rate across the world
there is a substantial need for new and effective treatments. We
look forward to take part of the study results and to follow Modus
Therapeutics’ continued development efforts", comments Viktor
Drvota, CEO of Karolinska Development.
Karolinska Development's direct ownership interest, and indirect
ownership interest via KDev Investment, in Modus Therapeutics
amounts to 38% and 17%, respectively.
For further information, please
contact:
Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982
52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska
Development ABPhone: +46 70 207 48 26, e-mail:
johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development ABKarolinska
Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences
investment company. The company focuses on identifying breakthrough
medical innovations in the Nordic region that are developed by
entrepreneurs and leadership teams. The Company invests in the
creation and growth of companies that advance these assets into
commercial products that are designed to make a difference to
patients' lives while providing an attractive return on investment
to shareholders.
Karolinska Development has access to world-class medical
innovations at the Karolinska Institutet and other leading
universities and research institutes in the Nordic region. The
Company aims to build companies around scientists who are leaders
in their fields, supported by experienced management teams and
advisers, and co-funded by specialist international investors, to
provide the greatest chance of success.
Karolinska Development has a portfolio of ten companies
targeting opportunities in innovative treatment for
life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment
professionals with a proven track record as company builders and
with access to a strong global network.
For more information, please visit
www.karolinskadevelopment.com.
- KD PM Modus start fas 1b LPS study ENG
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karolinska Development Ab (LSE:0P3C)
Historical Stock Chart
From Apr 2023 to Apr 2024